Lauren Santye, Assistant Editor

Top news of the day from across the health care landscape.

Combination treatments well tolerated amongst study participants with HIV-1 infection.

Proper dosing of Vorinostat can help expose latent HIV.

Memory T cell subtypes can be reactivated with current immunotherapy.

Top news of the day from across the health care landscape.

Renflexis is indicated for the same inflammatory conditions as reference drug infliximab.

Renflexis is a biosimilar of Remicade, which treats inflammatory conditions, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

Potential treatment for primary progressive multiple sclerosis is an oral pill consisting of pharmaceutical formulations of purified THC and CBD.

Enzyme acts as an epigenetic checkpoint of T cell function to treat cancer.

Involving patients in the decision-making process can improve multiple sclerosis treatment adherence and overall quality-of-life.

Stem cells loaded with oncolytic herpes simplex virus significantly slowed tumor growth in mice.

Pitavastatin may serve as a potential treatment for drug-resistant ovarian cancer.

Investigational biosimilar to Herceptin is designed to treat HER2-positive early breast cancer.

Sexual risk behaviors are associated with increased HIV transmission and prevalence, yet women are largely understudied.

Hepatitis C virus is a major cause of liver-related morbidity and mortality.

Top news of the day from across the health care landscape.

Moses Zonana, CEO of Compliance Meds Technologies, discusses ways technology can be utilized to monitor adherence.

Vosevi is a fixed-dose, combination tablet containing sofosbuvir and velpatasvir, as well as the new drug voxilaprevir, according to a press release.

Latest hepatitis C treatment approved by FDA is a combination of containing sofosbuvir, velpatasvir, and voxilaprevir.

The combination tablet is approved to treat adults with hepatitis C genotypes 1-6 without cirrhosis or mild cirrhosis.

The anticipated action date for drug that treats moderate-to-severe active ulcerative colitis is set for March 2018.

PrEP has been found to be effective in preventing HIV in high-risk populations.

Scientists identify several new variants that affect the risk of lung cancer development.

Romosozumab is being investigated to treat postmenopausal women with osteoporosis.

Top news of the day from across the health care landscape.

The production of HIV-1 neutralizing antibodies correlated with self-reactive antibody levels,

New report provides insight into patient awareness and attitudes towards biosimilars.

Findings point towards an HIV vaccine that stimulates the production of these antibodies.

Promising immunotherapy may change the standard of care for kidney cancer.

Mice fed a tomato-rich diet experienced a 50% reduction in tumors.